Search Results

In Vitro Studies to Evaluate the Intestinal Permeation of an Ursodeoxycholic Acid-Conjugated Oligonucleotide for Duchenne Muscular Dystrophy Treatment.

• Authors : Faiella M; Department of Translational Medicine, University of Ferrara, 44121 Ferrara, Italy.; Botti G

• Source: Pharmaceutics [Pharmaceutics] 2024 Aug 01; Vol. 16 (8). Date of Electronic Publication: 2024 Aug 01.Publisher: MDPI Country of Publication: Switzerland NLM ID: 101534003 Publication Model: Electronic Cited Medium: Print ISSN: 1999-4923 (Print)

Record details

Duchenne Muscular Dystrophy Treatment Agamree Now Available

• Authors : Ernst, Diana

• Source: MPR Monthly Prescribing Reference. March 14, 2024

Record details

FDA Clears Investigational New Drug application for muscular dystrophy treatment from University of Minnesota startup Myogenica.

• Source: PR Newswire. 2024.

Record details

Radboud University Medical Center Researcher Details Findings in Facioscapulohumeral Muscular Dystrophy (Treatment Approaches for Altered Facial Expression: A Systematic Review in Facioscapulohumeral Muscular Dystrophy and Other Neurological ...)

• Source: Health & Medicine Week. 2024, pages. 4071

Record details

Correction of human nonsense mutation via adenine base editing for Duchenne muscular dystrophy treatment in mouse.

• Authors : Jin M; Department of Neurology and Institute of Neurology of First Affiliated Hospital, Institute of Neuroscience, Fujian Key Laboratory of Molecular Neurology, Fujian Medical University, Fuzhou 350004, China.; Lin J

• Source: Molecular therapy. Nucleic acids [Mol Ther Nucleic Acids] 2024 Mar 06; Vol. 35 (2), pp. 102165. Date of Electronic Publication: 2024 Mar 06 (Print Publication: 2024).Publisher: Cell Press Country of Publication: United States NLM ID: 101581621 Publication Model: eCollection Cited Medium: Print ISSN: 2162-2531

Record details

Duchenne muscular dystrophy treatment with lentiviral vector containing mini-dystrophin gene in vivo.

• Authors : Wang X; Department of Pharmacy Cancer Center and State Key Laboratory of Biotherapy West China Hospital Sichuan University Chengdu Sichuan China.; Zhu Y

• Source: MedComm [MedComm (2020)] 2024 Jan 06; Vol. 5 (1), pp. e423. Date of Electronic Publication: 2024 Jan 06 (Print Publication: 2024).Publisher: John Wiley & Sons, Inc Country of Publication: China NLM ID: 101769925 Publication Model: eCollection Cited Medium: Internet ISSN:

Record details

Celebrating A Milestone In Duchenne Muscular Dystrophy Treatment.

• Source: Mondaq Business Briefing. 2024.

Record details

Pfizer's Setback in Duchenne Muscular Dystrophy Treatment Trial Clears Path for Sarepta, and Many Other Pharma Companies | DelveInsight.

• Source: PR Newswire. 2024.

Record details

Pfizer's Setback in Duchenne Muscular Dystrophy Treatment Trial Clears Path for Sarepta, and Many Other Pharma Companies | DelveInsight

• Source: Pediatrics Week. July 6, 2024, 795

Record details

FDA Fast-Tracks Review Of Sarepta's Groundbreaking Muscular Dystrophy Treatment With $1B Market In Sight.

• Source: Benzinga.com. 2024.

Record details